NR1I2 and Hepatic steatosis: In a study employing both wild-type mice and PXR-knockout (PXR-KO) mice, it has been demonstrated that the activation of hepatic PXR suppresses the hepatic expression of PPARα and its downstream targets, such as Fgf21, Cyp4a10, and Cyp4a14, thereby exacerbating hepatic steatosis [81,82].